Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

FP-02.2 Vaccine

Vaccine (Peptide vaccine) · Immune activation · developed by Altimmune

Phase 1 Most advanced trial (none active)

ALT Developer

1 Registered trials

What is FP-02.2 Vaccine?

FP-02.2 is a synthetic peptide vaccine developed against hepatitis B. It is studied in the prevention of hepatitis B infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Peptide vaccine)
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Altimmune, Inc. (ALT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02496897	Phase 1	Hepatitis B	Completed	ALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis B

More from Altimmune

AdCOVID Phase 1 HepTcell Phase 2 NasoShield Phase 1 NasoVAX Phase 2 Pemvidutide Phase 3

Sources

ClinicalTrials.gov NCT02496897

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALT page.

Follow ALT, the company behind FP-02.2 Vaccine

See ALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z